Search

Objective: Left ventricular (LV) hypertrophy predisposes the myocardium to ischemia through several mechanisms. The LV mass index (LVMI) is used as a readily available and reliable measurement of LV hypertrophy. The LVMI can also be used to evaluate LV remodeling. The hypothesis of this study was that LV hypertrophy might augment coronary collateralization in patients with chronic total occlusion (CTO) and the aim was to research any association between LVMI and collateral formation in CTO. As a secondary goal, specific LV geometric types that might be associated with collateral presence were also investigated. Methods: A total of 305 patients with CTO were included and categorized into 4 groups based on Rentrop grade. Results: The LVMI demonstrated an incremental linear trend as the Rentrop grade increased. In the receiver operating characteristic curve, the likelihood that a cut-off value of 100.1 g/m2 would accurately differentiate patients with collaterals from those without collaterals was 75.8%, with 68.5% sensitivity and 68.6% specificity. A 1 gram/m2 increase in LVMI was associated with a 7.5% greater likelihood of collateral development. In addition, compared with normal geometry, the presence of eccentric hypertrophy was associated with 6.7 times higher odds of the presence of coronary collaterals. Conclusion: The results of this study indicated that a greater LVMI predicted coronary collateral presence. Furthermore, having an eccentric geometric type of hypertrophy increased the likelihood of coronary collaterals more than other geometries. This finding signified that in addition to LV wall thickness, the type of hypertrophy was also decisive in predicting collateral presence.

Objective: The aim of this study was to assess the myocardial energy expenditure (MEE) in patients with cardiac syndrome X (CSX) and to examine its association with exercise electrocardiogram (ECG) parameters. Methods: A total of 99 patients who underwent coronary angiography and who were diagnosed as having normal coronary arteries were included. The patients were divided into 2 groups based on symptoms and exercise ECG parameters: 56 CSX patients and 43 control patients with a negative stress test. MEE was calculated using transthoracic echocardiography-derived parameters: circumferential end-systolic stress, left ventricular ejection time, and stroke volume. Results: In patients with CSX, the MEE at rest was 28% higher in than the control group (89.2+-36.3 vs. 69.8+-17.2 cal/minute). Correlation analysis revealed a moderately negative correlation between MEE and the Duke treadmill score (DTS) (β: -0.456; p

Medications and treatments are said to have a palliative effect if they relieve symptoms without having a curative effect on the underlying disease such as atherosclerosis or cancer. Some authors speculated that atherosclerotic coronary artery disease (CAD) could be considered a “cancer of the coronary arterial wall”. Although the percutaneous coronary intervention (PCI) has proven to be effective in decreasing mortality rates among patients with acute coronary syndromes, the previous meta-analyses of PCI versus optimal medical therapy for stable CAD have not been able to demonstrate a reduction in major adverse cardiac outcomes. However, few cardiologists discussed the evidence-based benefits of angiogram and PCI for stable CAD, and some implicitly or explicitly overstated the benefits. Recently, the precision medicine is defined as an evidence-based approach that uses innovative tools and biological and data science to customize disease prevention, detection, and treatment, and improve the effectiveness and quality of patient care. Providing patients with accurate and complete information appears to be an effective way to combat the reliance on the oculostenotic reflex. The foundation of precision medicine is the ability to tailor therapy based upon the expected risks and benefits of treatment for each individual patient. As said by Doctor William Osler, “The good physician treats the disease; the great physician treats the patient who has the disease.”